Technical Analysis for IGMS - IGM Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
60.69 | 20.25% | 10.22 |
IGMS closed up 20.25 percent on Friday, February 21, 2020, on 2.13 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| Historical IGMS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.
Biotechnology Cancer Manufacturing Medical Specialties Immunology Treatment Of Cancer Antibodies Glycoproteins Protein Engineering Biochemistry
Biotechnology Cancer Manufacturing Medical Specialties Immunology Treatment Of Cancer Antibodies Glycoproteins Protein Engineering Biochemistry
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 61.5 |
| 52 Week Low | 16.1 |
| Average Volume | 164,820 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 38.24 |
| 20-Day Moving Average | 42.19 |
| 10-Day Moving Average | 45.85 |
| Average True Range | 3.87 |
| ADX | 34.77 |
| +DI | 46.19 |
| -DI | 8.66 |
| Chandelier Exit (Long, 3 ATRs ) | 49.89 |
| Chandelier Exit (Short, 3 ATRs ) | 45.12 |
| Upper Bollinger Band | 53.64 |
| Lower Bollinger Band | 30.74 |
| Percent B (%b) | 1.31 |
| BandWidth | 54.26 |
| MACD Line | 4.23 |
| MACD Signal Line | 2.67 |
| MACD Histogram | 1.551 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 78.24 | ||||
| Resistance 3 (R3) | 76.56 | 69.03 | 75.32 | ||
| Resistance 2 (R2) | 69.03 | 64.56 | 69.87 | 74.34 | |
| Resistance 1 (R1) | 64.86 | 61.80 | 66.95 | 66.54 | 73.36 |
| Pivot Point | 57.33 | 57.33 | 58.37 | 58.17 | 57.33 |
| Support 1 (S1) | 53.16 | 52.86 | 55.25 | 54.84 | 48.02 |
| Support 2 (S2) | 45.63 | 50.10 | 46.47 | 47.04 | |
| Support 3 (S3) | 41.46 | 45.63 | 46.07 | ||
| Support 4 (S4) | 43.14 |
